Abstract
BACKGROUND Physiological differences between males and females could contribute to the development of AD. Here, we examined metabolic pathways that may lead to precision medicine initiatives.
METHODS We explored whether sex modifies the association of 540 plasma metabolites with AD endophenotypes including diagnosis, CSF biomarkers, brain imaging, and cognition using regression analyses for 695 participants (377 females), followed by sex-specific pathway overrepresentation analyses, APOE ε4 stratification and assessment of metabolites’ discriminatory performance in AD.
RESULTS In females with AD, vanillylmandelate (tyrosine pathway) was increased and tryptophan betaine (tryptophan pathway) was decreased. The inclusion of these two metabolites (AUC = 0.83, SE = 0.029) to a baseline model (covariates + CSF biomarkers, AUC = 0.92, SE = 0.019) resulted in a significantly higher AUC of 0.96 (SE = 0.012). Kynurenate was decreased in males with AD (AUC = 0.679, SE = 0.046).
CONCLUSIONS Metabolic sex-specific differences were reported, covering neurotransmission and inflammation pathways with AD endophenotypes. Two metabolites, in pathways related to dopamine and serotonin, associated to females, paving the way to personalised treatment.
Competing Interest Statement
KB and HZ have served as consultants at scientific advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, NovartisEisai, Denali, Roche Diagnostics, and Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx, have given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and are co-founders of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside the submitted work). DA participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmaceutica S.L. and Esteve Pharmaceuticals S.A.
Funding Statement
The present study was conducted as part of the EMIF-AD project, which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372, EPAD grant no. 115736, and from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 666992. Resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007-2013) and EFPIA companies' in-kind contribution. The DESCRIPA study was funded by the European Commission within the fifth framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission within the fifth framework program (contract no. 37670). The San Sebastian GAP study is partially funded by the Department of Health of the Basque Government (allocation 17.0.1.08.12.0000.2.454.01.41142.001.H). The Leuven cohort was funded by the Stichting voor Alzheimer Onderzoek (grant numbers #11020, #13007 and #15005). The SPIN cohort (Barcelona) has received funding from CIBERNED; Instituto de Salud Carlos III; jointly funded by Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, (Una manera de hacer Europa); Generalitat de Catalunya; Fundacio (La Marato TV3) Fundacio Bancaria Obra Social La Caixa; Fundacion BBVA; Fundacion Espanola para el Fomento de la Investigacion de la Esclerosis Lateral Amiotrofica (FUNDELA); Global Brain Health Institute; Fundacio Catalana Sindrome de Down; and Fundacio Victor Grifols i Lucas. KB and HZ are Wallenberg Scholars supported by grants from the Swedish Research Council (#2017-009152018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation (#AF-742881), the Erling-Persson Family Foundation, Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden (#FO2017-0243), the Swedish stateFO2019-0228), the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236No 860197 (MIRIADE), and the National UK Dementia Research Institute at UCL. Research at VIB-Antwerp was in part supported by the University of Health (NIH), USA (grant #1R01AG068398-01) Antwerp Research Fund. PK is supported by the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement ALFGBG-724331 and AW by ALFGBG-720661. DJM was partially supported by a grant from the National Institutes of Health (R15-GM107864). YFL is supported by The Brain Foundation (Hjarnfonden FO2018-0315), Stohne's Foundation (Stohnes Stiftelse), Gamla Tjanarinnor Stftelse, Stohnes Stiftelse, Sarfond 31S Research Fund Region orebro lan Sweden, Familjen Kamprad Stiftelse (ref 20210034, AFA 200386). DA received support from Institute of Health Carlos III (ISCIII), Spain PI18/00435 and INT19/00016, and by the Department of Health Generalitat de Catalunya PERIS program SLT006/17/125. JL is funded by the van Geest endowment fund. RG is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre. JX and CLQ thank Lundbeck Fonden for the support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study obtained ethical approval from the local medical ethical committee in each centre involved in the EMIF-AD cohort as listed below: Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Lausanne University Hospital (CHUV), Lausanne, Switzerland; Department of Psychiatry and Neuropsychology, University of Maastricht, The Netherlands; LENITEM - Laboratory of Epidemiology and Neuroimaging & Telemedicine, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, The Netherlands; Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Sweden; Department of Internal Medicine and Clinical Gerontology, Toulouse University Hospital, Toulouse, France; Fundacio ACE, Barcelona, Spain; The genetic counseling program for familial dementias (PICOGEN) at the Hospital Clinic, Barcelona, Spain; The outpatient clinics of the Sant Pau Memory Unit, Barcelona, Spain; University Hospitals Leuven, Belgium; Clinical Neurophysiology Unit, Department of Endocrinological and Metabolic Sciences, University of Genoa, Genoa, Italy; Division of Geriatric Psychiatry, Zentralinstitut fur Seelische Gesundheit, University of Heidelberg, Mannheim, Germany; Kingshill Research Centre, Swindon, UK; Department of Geriatrics, Hopital Broca, Paris, France; 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania; Department of Neurology, Kuopio University Hospital, Kuopio, Finland; Department of Geriatrics, Radboud University Medical Centre, Nijmegen, The Netherlands; The Research Institute for the Care of Older People (RICE), Bath, UK; Department of Care of The Elderly, University of Bristol, Frenchay Hospital, Bristol, UK; Alzheimer Memorial Centre and Geriatric Psychiatry Branch, Dementia and Neuroimaging Section Department of Psychiatry, Ludwig-Maximilian University, Munich, Germany; Institute Born-Bunge, ZNA Middelheim, University of Antwerp, Belgium; The PharmaCog study was reviewed and approved by the ethics committee of the coordinating site Brescia, Italy. Subjects had already provided written informed consent at the time of inclusion in the cohort for use of data, samples and scans. Research was conducted in accordance with the Declaration of Helsinki and all participants provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The other authors declare no conflict of interest.
Supplemental file updated
Data Availability
Data used in preparation of this article were obtained from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) cohort.
